Master Topic Page

News

20-12-2022 | Osteoarthritis | News

Support for further investigation of metformin in people with osteoarthritis

Metformin use is associated with a significant reduction in the risk for total knee or hip replacement among people with type 2 diabetes, shows research published in CMAJ.

19-12-2022 | Systemic lupus erythematosus | News

Anti-dsDNA antibodies have potential to guide targeted therapy use in SLE

An exploratory analysis of data from the phase 2b BEAT LUPUS trial suggests that IgA2 anti-dsDNA antibody levels may be able to predict response to B cell-targeted therapies in patients with systemic lupus erythematosus.

15-12-2022 | JAK inhibitors | News

EMA restricts JAK inhibitor use in high-risk patient groups

Click through for further details on this safety announcement

13-12-2022 | Baricitinib | News

Baricitinib linked to increased risk for VTE

Real-world study findings suggest that people with rheumatoid arthritis treated with the JAK inhibitor baricitinib may have a higher risk for venous thromboembolism than those on TNF inhibitors.

23-11-2022 | ACR 2022 | Conference coverage | Video

SURPASS: Secukinumab vs adalimumab biosimilar in axSpA

Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.

05-08-2022 | JAK inhibitors | Video

Have the ORAL Surveillance results changed rheumatology practice?

Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect.

06-07-2022 | JAK inhibitors | Ask the expert | Video

How to talk to patients about JAK inhibitor safety

Following the results of the ORAL Surveillance trial, which demonstrated increased rates of adverse events in people taking JAK inhibitors, Victoria Ruffing provides guidance on how to talk to patients about the risks associated with these medications.